Post-Approval Change Notification for Medical Devices in Ethiopia

1. Key takeaways

Ethiopia applies a mandatory approval-before-placement rule to changes in registered devices: under Article 21(1) of Proclamation No. 1112/2019, any change introducing a modification affecting the safety, quality or effectiveness of a registered medical device means that the product may not be placed on the market before the registration holder has notified the change and obtained EFDA approval. EFDA also maintains a dedicated Guideline for Notification of Post-Approval Changes for Medical Devices (EFDA-GDL-098), which sets out the change categories, the classification principles and the actions required of applicants in each category; the authority recommends consulting that guideline before submitting any change application. On fees, a major change application evaluation costs 870 Birr and a minor change application evaluation costs 650 Birr. The combination of a statutory prohibition, a category system and a differentiated fee schedule means that change management in Ethiopia is a regulated lifecycle process, not an internal engineering decision with a paperwork afterthought.

2. Legal basis

3. Expert insights

Insight 1: The statutory wording is may not be marketed, not must be filed.

Article 21(1) reads that the product may not be marketed unless the change has been notified and approved, which makes approval a precondition of placement. This differs fundamentally from the practice in some markets where a change is filed after the fact while sales continue. In Ethiopia, selling a changed product before approval constitutes a violation of the conditions of the market authorization itself, not a procedural irregularity. The distinction matters for risk assessment: the consequence is not a request to catch up on paperwork but exposure on the validity of the authorization under which the product is being sold.

Insight 2: The authority’s test is whether the evidence has been appropriately collected and reviewed.

Section 12.3 of EFDA-GDL-046 is explicit: before deciding whether a changed device can continue to be placed on the market, EFDA will, on the basis of the notification submitted by the applicant, judge whether the evidence on safety and performance has been appropriately collected and reviewed. The core of a change application is therefore not describing what was changed, but demonstrating with evidence that the changed product is still safe and performs as claimed. Applications built around narrative descriptions of the modification, without a mapped evidence package, answer the wrong question.

Insight 3: The manufacturer must first run a three-dimension self-assessment.

Section 12.3 requires the manufacturer, when proposing any intended change, to assess its impact on patients and on practitioners / users, and its impact on the device specifications, before determining whether the change is intended to affect safety and performance. This self-assessment is the starting point of the major / minor classification and the basis on which EFDA judges whether the notification is complete. Documenting the assessment, rather than performing it informally, is what makes the classification defensible if the authority challenges it.

Insight 4: Change management loops back into re-registration.

Item 12.1(g) requires a no-change confirmation letter or a summary of changes since the most recent approval at re-registration. Every unapproved change made during the 5-year cycle therefore surfaces concentrated at the year-five checkpoint. Change notification is not an isolated action but one element of registration lifecycle management, and a clean change ledger is the cheapest re-registration insurance available.

Insight 5: The fee gap of 220 Birr reflects a gap in review depth.

The difference between the 870 Birr major change fee and the 650 Birr minor change fee corresponds to the difference in the intensity of evidence re-examination. Declaring a major change as a minor one triggers both a request for correction and a refund-and-repayment cycle, which lengthens the timeline instead of shortening it. The saving of 220 Birr is trivial against the cost of a bounced submission.

4. Practical recommendations

1. Maintain a change-trigger list: cover changes in design, materials, processes, sterilization method, software versions, labels and instructions for use, manufacturer name and address, and the local agent; any trigger starts the assessment.
2. Run the three-dimension impact assessment first and archive it: patient / user impact, specification impact, and safety and performance impact; the conclusion anchors the classification.
3. Classify against EFDA-GDL-098: follow the categories of the current guideline rather than habits imported from other markets.
4. Assemble evidence by category: major changes require complete post-change safety and performance evidence (including non-clinical or clinical data where necessary); minor changes require at least a change description and a consistency comparison.
5. Do not ship before approval: make the approval letter a hard release condition for changed product, enforced at the warehouse, not only in policy documents.
6. Update the re-registration ledger in parallel: register every approved change immediately so the year-five change summary can be compiled without archaeology.

5. Verification checklist

• □ Confirmed whether the change affects safety, quality or effectiveness (Article 21(1))
• □ The three-dimension assessment of patient / user, specification and safety-performance impact is complete
• □ The major or minor category has been determined against EFDA-GDL-098
• □ The evidence required for that change category has been assembled
• □ The fee has been paid according to the category (major 870 Birr / minor 650 Birr)
• □ Product ships only after approval has been obtained
• □ The change ledger has been updated for the re-registration change summary

Regulatory information verified as of October 29, 2026. The change notification rules listed in this article are governed by Article 21(1) of Proclamation No. 1112/2019, Section 12.3 of EFDA-GDL-046 and the current text of EFDA-GDL-098; when the guideline is revised, the category classification must be re-checked.

Local resource in Ethiopia: GRZAN supports manufacturers from the Chinese mainland and overseas in engaging with the Ethiopian Food and Drug Authority (EFDA) on market authorization (MA), Certificate of Competence (CoC) and import permit applications, including local agent structuring and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical documentation preparation, and the establishment of vigilance and post-market surveillance systems. Service capabilities cover product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), market authorization applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles conformity reasoning, label and instruction-for-use localization in English, and vigilance reporting with field safety corrective action support. Contact: hito.lin@grzan.cn; website www.grzan.cn. For change classification, evidence planning and local authorized representative support in the Ethiopian market, GRZAN can also be reached at info@grzanglobal.com.